Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis

Abstract

BackgroundThe bevacizumab and irinotecan protocol is considered a standard treatment regimen for recurrent malignant glioma. Recent advances in immunotherapy have hinted that vaccination with dendritic cells could become an alternative salvage therapy for the treatment of recurrent malignant glioma.MethodsA search was performed on PubMed, Cochrane Library, Web of Science, ScienceDirect, and Embase in order to identify studies with patients receiving bevacizumab plus irinotecan or dendritic cell therapy for recurrent malignant gliomas. The data obtained from these studies were used to perform a systematic review and survival gain analysis.ResultsFourteen clinical studies with patients receiving either bevacizumab plus irinotecan or dendritic cell vaccination were identified. Seven studies followed patients that received bevacizumab plus irinotecan (302 patients) and seven studies included patients that received dendritic cell immunotherapy (80 patients). For the patients who received bevacizumab plus irinotecan, the mean reported median overall survival was 7.5 (95% confidence interval [CI] 4.84–10.16) months. For the patients who received dendritic cell immunotherapy, the mean reported median overall survival was 17.9 (95% CI 11.34–24.46) months. For irinotecan + bevacizumab group, the mean survival gain was −0.02±2.00, while that for the dendritic cell immunotherapy group was −0.01±4.54.ConclusionFor patients with recurrent malignant gliomas, dendritic cell immunotherapy treatment does not have a significantly different effect when compared with bevacizumab and irinotecan in terms of survival gain (P=0.535) and does not improve weighted survival gain (P=0.620).

The Interference between SARS-CoV-2 and Tyrosine Kinase Receptor Signaling in Cancer

“…Oncolytic virotherapy is becoming an attractive option for the treatment of patients with different forms of cancer. Several clinical studies have researched the use of viral therapy, providing promising results [ 81 , 82 , 83 ]. Coronaviruses have been researched in this particular subject as potentially capable of exerting an antitumoral effect.…”

FOLFOX regimen plus dendritic cells–cytokine-induced killer cells immunotherapy for the treatment of colorectal cancer: a meta-analysis

“…Adoptive cellular immunotherapy is achieved upon in vitro expansion of autologous immune effector cells, such as cytokine-induced killer cells (CIK), 7 , 8 natural killer cells 9 and other immune cells, 10 – 12 and transfusion back to the patients. Since conventional therapies are not able to eradicate the tumor cells thoroughly, the killing effect of adoptive cellular immunotherapy on tumor cells will make it an important supplement.…”

Comparative effect of immunotherapy and standard therapy in patients with high grade glioma: a meta-analysis of published clinical trials

“…In addition, peripheral high levels of IFN-γ corresponding to an elevated immune response were observed. In our previous study based on a survival gain analysis of patients receiving DC-based treatment versus bevacizumab and irinotecan for patients with recurrent HGG, we didn’t find any major improvement for both OS and weighted survival gain for patients in the immunotherapy arm 39 . However, it should be noted that we only included patients with recurrent tumors in the study, in which case treatment response rates, OS and PFS are significantly lower than in newly diagnosed patients.…”